Bris­tol-My­ers shows off a low-pro­file AML con­tender it gained from Cel­gene buy­out — and they’re tak­ing it straight to the FDA

Bris­tol-My­ers Squibb reaped an enor­mous pipeline with its much-crit­i­cized $64 bil­lion megadeal to buy Cel­gene. And it got a few hid­den gems in the deal.

One of those gems was brought out for dis­play on Tues­day, with a late-break­er at ASH on CC-486, which is now be­ing prepped for reg­u­la­to­ry fil­ings at the FDA and else­where.

Cel­gene top-lined the pos­i­tive re­sults in a main­te­nance set­ting for acute myeloid leukemia a few months ago, but at ASH in­ves­ti­ga­tors pulled back the cur­tains on the all-im­por­tant da­ta they be­lieve will give them an ad­van­tage in the com­mer­cial wars to come.

And it’s im­pres­sive.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER